Results 251 to 260 of about 50,491,421 (329)
Aggressive prostate cancer is associated with pericyte dysfunction
Molecular Oncology, EarlyView.Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero +11 more
wiley +1 more source
A conversation with Keith McCrae, MD, staff and professor of molecular medicine, Cleveland Clinic
Journal of Clinical and Translational ScienceClinical Research Forum
doaj +1 more source
Molecular Oncology, EarlyView.Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard +12 more
wiley +1 more source
HBM Package Interconnection Pseudo All-Channel Signal Integrity Simulation and Implementation Method of the Synchronous Current Load Research [PDF]
Wenfei Tang +8 more
openalex +1 more source
Engagement in research capability-building: Impact on healthcare workforce attraction and retention in rural and remote Australia - A scoping review protocol. [PDF]
PLoS OneHaile TG, Wallace H, Manuel J, Estai M.
europepmc +1 more source
Molecular Oncology, EarlyView.ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang +8 more
wiley +1 more source